{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"124-324-563-847-190","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"124-324-563-847-190"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11616,"type":"PATENT","title":"Case Western Reserve University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4001,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8291,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: weste* reser* AND Univ*
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2737
Search Applicants and Owners separately: weste* reser* AND Univ*
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2737
administering at least one PPARγ agonist or a derivative thereof to cystic fibrosis cells of the subject in an amount effective to inhibit NF-κB activation in the cystic fibrosis cells, the PPARγ agonist or the derivative thereof comprising a thiazolidinedione or a derivative thereoaf."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, the amount of the PPARγ agonist or derivative thereof being administered to the subject being that amount effective to suppress airway inflammation."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["(canceled)"],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["(canceled)"],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["(canceled)"],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["(canceled)"],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, the PPARγ agonist or a derivative thereof comprising a compound of Formula IV or pharmaceutically acceptable salt of a compound of Formula IV, wherein Formula IV is:\n
wherein the dotted line represents a bond or no bond; V is HCH—, —NCH—, —CH═N—, or S;\nD is CH2, CHOH, CO, C═NOR17, or CH═CH; X is S, SO, NR18, —CH—N, or —N═CH;Y is CH or N;\n
Z is hydrogen, (C1-C7)alkyl, (C1-C7)cycloalkyl, phenyl, naphthyl, pyridyl, furyl, thienyl, or phenyl mono- or di-substituted with the same or different groups which are (C1-C3)alkyl, trifluoromethyl, (C1-C3)alkoxy, fluoro, chloro, or bromo;\n
Z, is hydrogen or (C1-C3)alkyl;\n
R17 and R18 are each independently hydrogen or methyl; and n is 1, 2, or 3."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, the PPARγ agonist or a derivative thereof comprising a compound of Formula V or pharmaceutically acceptable salt of a compound of Formula V, wherein Formula V is:\n
wherein the dotted line represents a bond or no bond;\n
A and B are each independently CH or N with the proviso that when A or B is N the other is CH; X is S, SO, SO2, C1-2, CHOH, or CO;\n
n is O or 1;\n
Y1 is CHR20 or R21, with the proviso that when n is I and Y, is NR21, X1 is SO2 or CO; Z2 is CHR22, CH2CH2, cyclic C2H2O, CH═CH, OCH2, SCH2, SOCH2, or SO2CH2;\n
R19, R20, R21, and R22 are each independently hydrogen or methyl; and\n
X2 and X3 are each independently hydrogen, methyl, trifluoromethyl, phenyl, benzyl, hydroxy, methoxy, phenoxy, benzyloxy, bromo, chloro, or fluoro."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, the PPARγ agonist or a derivative thereof comprising a compound of Formula II or pharmaceutically acceptable salt of a compound of Formula VI, wherein Formula VI is:\n
wherein R23 is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl or mono- or all-substituted phenyl wherein the substituents are independently alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 3 carbon atoms, halogen, or trifluoromethyl."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, the PPARγ agonist or a derivative thereof comprising a compound of Formula VII or pharmaceutically acceptable salt of a compound of Formula VII, wherein Formula VII is:\n
wherein A2 represents an alkyl group, a substituted or unsubstituted aryl group, or an aralkyl group wherein the alkylene or the aryl moiety is substituted or unsubstituted;\n
A3 represents a benzene ring having in total up to 3 optional substituents;\n
R24 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the alkyl or the aryl moiety is substituted or unsubstituted, or a substituted or unsubstituted aryl group; or\nA2 together with R24 represents substituted or unsubstituted C2-3 polymethylene group;\n
R25 and R26 each represent hydrogen, or R25 and R26 together represent a bond; X4 represents O or S; and\n
n represents an integer in the range from 2 to 6."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, the PPARγ agonist or a derivative thereof comprising a compound of Formula VIII or pharmaceutically acceptable salt of a compound of Formula VIII, wherein Formula VIII is:\n
wherein: R27 and R28 each independently represent an alkyl group, a substituted or unsubstituted aryl group, or an aralkyl group being substituted or unsubstituted in the aryl or alkyl moiety;\n
or R27 together with R28 represents a linking group, the linking group consisting or an optionally substituted methylene group or an O or S atom; R29 and R30 each represent hydrogen, or R29 and R30 together represent a bond;\n
A4 represents a benzene ring having in total up to 3 optional substituents;\n
X5 represents O or S; and\n
n represents an integer in the range of 2 to 6."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, the PPARγ agonist or a derivative thereof comprising a compound of Formula IX or pharmaceutically acceptable salt of a compound of Formula IX, wherein Formula IX is:\n
wherein: A5 represents a substituted or unsubstituted aromatic heterocyclyl group; A6 represents a benzene ring having in total up to 5 substituents;\n
X6 represents O, S, or NR32 wherein R32 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;\n
Y2 represents O or S;\n
R31 represents an alkyl, aralkyl, or aryl group; and n represents an integer in the range from 2 to 6."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, the PPARγ agonist or a derivative thereof comprising a compound of Formula X or pharmaceutically acceptable salt of a compound of Formula X, wherein Formula X is:\n
wherein; A7 represents a substituted or unsubstituted aryl group;\n
A8 represents a benzene ring having in total up to 5 substituents;\n
X8 represents O, S, or NR9, wherein R39 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;\n
Y3 represents O or S;\n
R37 represents hydrogen;\n
R38 represents hydrogen or an alkyl, aralkyl, or aryl group or R37 together with R38 represents a bond; and\n
n represents an integer in the range from 2 to 6."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["(canceled)"],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["(canceled)"],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, the PPARγ agonist or a derivative thereof comprising at least one compound or a pharmaceutically salt thereof selected from the group consisting of: (+)-5[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4thiazolidinedione; 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[(1-methylcyclohexyl)methoxy]benzyl]thiazolidine-2,4-dione; (ciglitazone); 4-(2-naphthylmethyl)-1,2,3,5-oxathiadiazole-2-oxide; 5-[4-[2-[(N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]-5-methlthiazolidine-2,4-dione; 5-[4-[2-[2,4-dioxo-5-phenylthiazolidine-3-yl)ethoxy]benzyl]thiazolidine-2,4-dione, 5-[4-[2-[(N-methyl-N-(phenoxycarbonyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2-phenoxyethoxy)benzyl]thiazolidine-2,4-dione; 5-[4-[2-(4-chorophenyl)ethylsulfonyl]benzyl]thiazolidine-2,4-dione; 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidie-2,4-dione, 5-[[4-(3-hydroxy-1-methylcyclohexyl)methoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxyl)benzyl]thiazolidine-2,4-dione; 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl]thiazolidine-2,4-dione; 5-[2-(2-naphthylmethyl)benzoxazol]-5-ylmethyl]thiazolidine-2,4-dione; 5-[4-[2-(3-phenylureido)ethoxyl]benzyl]thiazolidine-2,4-dione; 5-[4-[2-(N-benzoxazol-2-yl)-N-metholamino]ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione; 5-2[-(N-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-ylmethyl]oxazolidine-2,4-dione; 5-[4-[2-(N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; and 5-[4-[2-(N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]oxazolidine-2,4-dione."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating inflammation associated with NF-κB activation in a subject the method comprising:\n
administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof to cells expressing NF-κB in the subject effective to inhibit NF-κB activation of the cells, the PPARγ agonist or a derivative thereof comprising at least one compound or a pharmaceutically salt thereof selected from the group consisting of: (+)-5[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4thiazolidinedione; 5-[4-[2-(5-ethylpyridin-2-yl)ethoxyl]benzyl]thiazolidine-2,4-dione; 5-[4-[(1-methylcyclohexyl)methoxy]benzyl]thiazolidine-2,4-dione; (ciglitazone); 4-(2-naphthylmethyl)-1,2,3,5-oxathiadiazole-2-oxide; 5-[4-[2-[(N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl)-5-methlthiazolidine-2,4-dione, 5-(4-[2-[2,4-dioxo-5-phenylthiazolidine-3-yl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-(2-[(N-methyl-N-(phenoxycarbonyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2-phenoxyethoxy)benzyl]thiazolidine-2,4-dione; 5-[4-[2-(4-chorophenyl)ethylsulfonyl]benzyl]thiazolidine-2,4-dione; 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione; 5-[[4-(3-hydroxy-1-methylcyclohexyl)methoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxyl]benzyl]thiazolidine-2,4-dione; 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl]thiazolidine-2,4-dione; 5-[[2-(2-naphthylmethyl)benzoxazol]-5-ylmethyl]thiazolidin-2,4-dione; 5-[4-[2-(3-phenylureido)ethoxyl]benzylthiazolidine-2,4-dione; 5-[4-[2-(N-benzoxazol-2-yl)-N-metholamino]ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione; 5-(2-(5-methyl-2-phenyloxazol-4-ylmethyl)benzofuran-5-ylmethyl]oxazolidine-2,4-dione; 5-[4-[2-(N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; and 5-[4-[2-(N-(benzoxazol-2-yl)-N-methylamino]ethoxy]benzyl]oxazolidine-2,4-dione."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17, the inflammation being associated with a cystic fibrosis related disorder."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["(canceled)"],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["(canceled)"],"number":20,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}